Company intelligence / Profile preview

Revolt

Redwood City, California, United Statesrevolt.tv ↗

Ownership: Private
Development stage: Commercial

Overview

Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies against elusive cancer drivers, especially mutant forms of the RAS protein. Its lead program, RMC‑6236, is a multi-selective KRAS inhibitor showing encouraging antitumor efficacy in lung and pancreatic cancers with various KRAS mutations. The company has several other candidates targeting different nodes within the RAS pathway.[3][4][5]

Therapeutic areas: Oncology
Modalities: Small moleculeSynthetic small molecule (mutant-selective RAS inhibitors)
Industry: Biotech

Partnerships

Former partnership with Sanofi for SHP2 inhibitor development (terminated December 2022)[3]

Beyond the preview

Go deeper on Revolt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revolt.

Explore the full profile